iVIEW Therapeutics Closes its A round financing to move forward iVIEW-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis

Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that it has closed its A round financing of close to $6 million dollars from both strategic and reputable venture investors including Zhejiang Huahai Pharmaceutical Co., Ltd., Shenzhen Share Precision Medical LLP and Alpha Bioventure LLC.

Dr. Bo Liang, President & Director at iVIEW comments, “I am glad that the investors has confidence on iVIEW’s sustain release drug delivery technology platform and iVIEW-1201’s potential as first-line treatment of viral conjunctivitis. The A round financing will allow the company to move our lead compound, iVIEW-1201 into phase II clinical trials in 2019.” “We are happy to lead this round of investment into iVIEW Therapeutics, as we are not only attracted by the potential of iVIEW-1201, a long acting broad spectrum antiseptic, to treat acute conjunctivitis, which there is no current FDA approved treatment for viral conjunctivitis, but also impressed by the successful track record of iVIEW’s founding team to lead the company to be a successful specialty pharmaceutical company focusing on ophthalmology.” Commented by Mr. Bin He, General Manager of Huahai Investment.

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2019 iVIEW Therapeutics, Inc. All rights reserved.